CAIRE MEDICAL FRANCE : revenue, balance sheet and financial ratios

CAIRE MEDICAL FRANCE is a French company founded 16 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in TOULOUSE (31300), this company of category ETI shows in 2022 a revenue of 635 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - CAIRE MEDICAL FRANCE (SIREN 517584892)
Indicator 2022 2021 2020 2018 2017 2016
Revenue 634 917 € 526 525 € 681 780 € 532 992 € N/C 886 410 €
Net income 5 191 € 77 260 € 73 954 € -118 683 € 130 190 € 170 499 €
EBITDA 13 192 € 73 103 € 60 398 € -14 995 € N/C 185 523 €
Net margin 0.8% 14.7% 10.8% -22.3% N/C 19.2%

Revenue and income statement

In 2022, CAIRE MEDICAL FRANCE achieves revenue of 635 k€. Revenue is declining over the period 2016-2022 (CAGR: -5.4%). Vs 2021, growth of +21% (527 k€ -> 635 k€). After deducting consumption (0 €), gross margin stands at 635 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 13 k€, representing 2.1% of revenue. Warning negative scissor effect: despite revenue change (+21%), EBITDA varies by -82%, reducing margin by 11.8 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 5 k€, i.e. 0.8% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2022) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

634 917 €

Gross margin (2022) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

634 917 €

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

13 192 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

21 995 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

5 191 €

EBITDA margin (2022) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

2.1%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

77.123%

Cash flow / Revenue (2022) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-0.477%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
CAIRE MEDICAL FRANCE

Sector positioning

Debt ratio
0.0 2022
2020
2021
2022
Q1: 0.0
Med: 6.23
Q3: 53.97
Excellent

In 2022, the debt ratio of CAIRE MEDICAL FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
77.12% 2022
2020
2021
2022
Q1: 15.33%
Med: 37.18%
Q3: 59.34%
Excellent

In 2022, the financial autonomy of CAIRE MEDICAL FRANCE (77.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2022
2020
2021
2022
Q1: 0.0 years
Med: 0.01 years
Q3: 1.6 years
Excellent

In 2022, the repayment capacity of CAIRE MEDICAL FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 437.64. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 15.0x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

437.636

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

14.986

Liquidity indicators evolution
CAIRE MEDICAL FRANCE

Sector positioning

Liquidity ratio
437.64 2022
2020
2021
2022
Q1: 136.77
Med: 203.41
Q3: 332.18
Excellent

In 2022, the liquidity ratio of CAIRE MEDICAL FRANCE (437.64) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
14.99x 2022
2020
2021
2022
Q1: 0.0x
Med: 0.34x
Q3: 4.26x
Excellent +11 pts over 3 years

In 2022, the interest coverage of CAIRE MEDICAL FRANCE (15.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 139 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 73 days. The gap of 66 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 156 days of revenue, i.e. 276 k€ to permanently finance. Notable WCR improvement over the period (-69%), freeing up cash.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

275 878 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

139 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

73 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2022) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

156 j

WCR and payment terms evolution
CAIRE MEDICAL FRANCE

Positioning of CAIRE MEDICAL FRANCE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of CAIRE MEDICAL FRANCE is estimated at 46 062 € (range 24 517€ - 142 888€). With an EBITDA of 13 192€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
124 transactions
24k€ 46k€ 142k€
46 062 € Range: 24 517€ - 142 888€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
13 192 € × 0.7x
Estimation 9 286 €
4 390€ - 33 796€
Revenue Multiple 30%
634 917 € × 0.21x
Estimation 135 221 €
73 327€ - 409 587€
Net Income Multiple 20%
5 191 € × 0.8x
Estimation 4 264 €
1 623€ - 15 573€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare CAIRE MEDICAL FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about CAIRE MEDICAL FRANCE

What is the revenue of CAIRE MEDICAL FRANCE ?

The revenue of CAIRE MEDICAL FRANCE in 2022 is 635 k€.

Is CAIRE MEDICAL FRANCE profitable?

Yes, CAIRE MEDICAL FRANCE generated a net profit of 5 k€ in 2022.

Where is the headquarters of CAIRE MEDICAL FRANCE ?

The headquarters of CAIRE MEDICAL FRANCE is located in TOULOUSE (31300), in the department Haute-Garonne.

Where to find the tax return of CAIRE MEDICAL FRANCE ?

The tax return of CAIRE MEDICAL FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does CAIRE MEDICAL FRANCE operate?

CAIRE MEDICAL FRANCE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.